Fatemeh MAHJOUB, Tahereh FALSAFI, Mohaddese MAHBOUBI, Majid SADEGHIZADEH

The role of outer inflammatory protein A (OipA) in vaccination of the C57BL/6 mouse model infected by Helicobacter pylori

Background/aim: Outer inflammatory protein A (OipA) is an important adhesin of Helicobacter pylori. Our goal was to assess the role of OipA in protection of C57BL/6 mice against H. pylori. Materials and methods: C57BL/6 mice were mucosally immunized with recombinant OipA protein, OipA + propolis, propolis, and phosphate-buffered saline. After vaccination, anti-OipA IgA was measured. Mice were challenged three times with 5 × 107CFU of the H. pylori B19 strain. Two weeks later, bacterial colonization and inflammation in the stomach was analyzed using standard methods. Results: The CFU number in the OipA group was significantly (P < 0.05) lower than that of the control. The CFU number in the OipA + propolis group was higher than those of the OipA and propolis groups. IgA titers were significantly higher (P < 0.0001) in the OipA group compared to the control and OipA + propolis groups. Propolis did not play an adjuvant effect but it interfered with the efficient vaccine effect of OipA. Conclusion: Results show the effect of vaccination by OipA in protection of the mouse model and the importance of OipA in H. pylori pathogenesis. OipA may be proposed as a suitable oral vaccine candidate against H. pylori infection; however, further study is required to determine adjuvant or adverse effects of propolis toward OipA.

PDF

___

1. Fischbach W, Chan AOO, Wong BCY. Helicobacter pylori and gastric malignancy. Helicobacter 2005; 10: 34-39.
2. Bytzer P, OMorain C. Treatment of Helicobacter pylori. Helicobacter 2005; 10: 40-46.
3. Horiki N, Omata F, Uemura M, Suzuki S, Ishii N, Iizuka Y, Fukuda K, Fujita Y, Katsurahara M, Ito T et al. Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan. Helicobacter 2009; 14: 86-90.
4. Sugimoto M, Uotani T, Sahara S, Ichikawa H, Yamade M, Sugimoto K, Furuta T. Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion. Helicobacter 2014; 19: 312- 318.
5. Ogata SK, Godoy AP, da Silva Patricio FR, Kawakami E. High Helicobacter pylori resistance to metronidazole and clarithromycin in Brazilian children and adolescents. J Pediatric Gastr Nutr 2013; 56: 645-648.
6. Rafeey M, Ghotaslou R, Nikvash S, Hafez AA. Primary resistance in Helicobacter pylori isolated in children from Iran. J Infect Chemother 2007; 13: 291-295.
7. Najafi M, Sobhani M, Khodadad A, Farahmand F, Motamed F. Reinfection rate after successful Helicobacter pylori eradication in children. Iran J Pediatr 2010; 20: 58-62.
8. Ayala G, Escobedo-Hinojosa WI, de la Cruz-Herrera CF, Romero I. Exploring alternative treatments for Helicobacter pylori infection. World J Gastroentero 2014; 20: 1450-1469.
9. Oleastro M, Menard A. The role of Helicobacter pylori outer membrane proteins in adherence and pathogenesis. Biology 2013; 2: 1110-1134.
10. Odenbreit S, Kavermann H, Puls J, Haas R. CagA tyrosine phosphorylation and interleukin-8 induction by Helicobacter pylori are independent from alpAB, HopZ and bab group outer membrane proteins. Int J Med Microbiol 2002; 292: 257-266.
11. Yamaoka Y, Kikuchi S, el-Zimaity HM, Gutierrez O, Osato MS, Graham DY. Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterology 2002; 123: 414-424.
12. Yamaoka Y, Kwon DH, Graham DY. A Mr 34,000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori. P Natl Acad Sci USA 2000; 97: 7533-7538.
13. Oleastro M, Ménard A. The role of Helicobacter pylori outer membrane proteins in adherence and pathogenesis. Biology (Basel) 2013; 2: 1110-1134.
14. Cai JL, Tang XL, Yang LF, Su XY. Propolis inactivated vaccine against infectious serositis in young ducks. Chin J Vet Sci 2001; 21: 552-553.
15. Fischer G, Conceição FR, Leite FP, Dummer LA, Vargas GD, Hübner Sde O, Dellagostin OA, Paulino N, Paulino AS, Vidor T. Immunomodulation produced by a green propolis extract on humoral and cellular responses of mice immunized with SuHV-1. Vaccine. 2007; 25: 1250-1256.
16. Fischer G, Paulino N, Marcucci MC, Siedler BS, Munhoz LS, Finger PF, Vargas GD, Hübner SO, Vidor T, Roehe PM. Green propolis phenolic compounds act as vaccine adjuvants, improving humoral and cellular responses in mice inoculated with inactivated vaccines. Mem I Oswaldo Cruz 2010; 105: 908-913.
17. Mahboubi M, Falsafi T, Sadegizadeh M. Cloning and sequence analysis of gene encoding OipA from Iranian clinical Helicobacter pylori. Iran J Biotechnol 2014; 12: 10-16.
18. ORiordan AA, Morales VA, Mulligan L, Faheem N, Windle HJ, Kelleher DP. Alkyl hydroperoxide reductase: a candidate Helicobacter pylori vaccine. Vaccine 2012; 30: 3876-3884.
19. Alhomsi MF, Adeyemi EO. Grading Helicobacter pylori gastritis in dyspeptic patients. Comp Immunol Microbiol 1996; 19: 147- 154.
20. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-1181.
21. Chen XY, van der Hulst RW, Bruno MJ, van der Ende A, Xiao SD, Tytgat GN, Ten Kate FJ. Interobserver variation in the histopathological scoring of Helicobacter pylori related gastritis. J Clin Pathol 1999; 52: 612-615.
22. Gewirtz AT, Yu Y, Krishna US, Israel DA, Lyons SL, Peek RM Jr. Helicobacter pylori flagellin evades toll-like receptor 5-mediated innate immunity. J Infect Dis 2004; 189: 1914- 1920.
23. Akhiani AA, Schon K, Lycke N. Vaccine-induced immunity against Helicobacter pylori infection is impaired in IL-18- deficient mice. J Immunol 2004; 173: 3348-3356.
24. Sayi A, Kohler E, Hitzler I, Arnold I, Schwendener R, Rehrauer H, Müller A. The CD4+ T cell-mediated IFN-γ response to Helicobacter infection is essential for clearance and determines gastric cancer risk. J Immunol 2009; 182: 7085-7101.
25. Bai Y, Zhang YL, Chen Y, Jin JF, Zhang ZS, Zhou DY. Cloning and expression and immunogenicity of Helicobacter pylori BabA2 gene. World J Gastroenterol 2004; 10: 2560-2562.
26. Every AL, Stent A, Moloney MB, Ng GZ, Skene CD, Edwards SJ, Sutton P. Evaluation of superoxide dismutase from Helicobacter pylori as a protective vaccine antigen. Vaccine 2011; 29: 1514- 1518.
27. Ferrero RL, Thiberge JM, Kansau I, Wuscher N, Huerre M, Labigne A. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. P Natl Acad Sci USA 1995; 92: 6499-6503.
28. Garhart CA, Redline RW, Nedrud JG, Czinn SJ. Clearance of Helicobacter pylori infection and resolution of postimmunization gastritis in a kinetic study of prophylactically immunized mice. Infect Immun 2002; 70: 3529-3538.
29. Radcliff FJ, Hazell SL, Kolesnikow T, Doidge C, Lee A. Catalase, a novel antigen for Helicobacter pylori vaccination. Infect Immun 1997; 65: 4668-4674.
30. Satin B, Del Giudice G, Della Bianca V, Dusi S, Laudanna C, Tonello F, Kelleher D, Rappuoli R, Montecucco C, Rossi F. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. J Exp Med 2000; 191: 1467-1476.
31. Xue J, Bai Y, Chen Y, Wang JD, Zhang ZS, Zhang YL, Zhou DY. Expression of Helicobacter pylori AlpA protein and its immunogenicity. World J Gastroenterol 2005; 11: 2260-2263.
32. Backert S, Tegtmeyer N. The versatility of the Helicobacter pylori vacuolating cytotoxin vacA in signal transduction and molecular crosstalk. Toxins 2010; 2: 69-92.
33. Oldani A, Cormont M, Hofman V, Chiozzi V, Oregioni O, Canonici A, Sciullo A, Sommi P, Fabbri A, Ricci V et al. Helicobacter pylori counteracts the apoptotic action of its VacA toxin by injecting the CagA protein into gastric epithelial cells. PLoS Pathog 2009; 5: e1000603.
34. Wei GC, Chen J, Liu AY, Zhang M, Liu XJ, Liu D, Xu J, Liu BR, Ling H, Wu HX et al. Prevalence of Helicobacter pylori vacA, cagA and iceA genotypes and correlation with clinical outcome. Exp Ther Med 2012; 4: 1039-1044.
35. Clyne M, Dolan B, Reeves EP. Bacterial factors that mediate colonization of the stomach and virulence of Helicobacter pylori. FEMS Microbiol Let 2007; 268: 135-143.
36. Ren Z, Pang G, Batey R, Routley D, Russell A, Musicka M, Dunkley M, Beagley K, Clancy R. Non-urease producing Helicobacter pylori in chronic gastritis. Aust N Z J Med 2000; 30: 578-584.
37. Lee CK, Weltzin R, Thomas WD Jr, Kleanthous H, Ermak TH, Soman G, Hill JE, Ackerman SK, Monath TP. Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J Infect Dis 1995; 172: 161- 172.
38. Chen J, Lin L, Li N, She F. Enhancement of Helicobacter pylori outer inflammatory protein DNA vaccine efficacy by codelivery of interleukin-2 and B subunit heat-labile toxin gene encoded plasmids. Microbiol Immunol 2012; 56: 85-92.
39. Chen J, Lin M, Li N, Lin L, She F. Therapeutic vaccination with Salmonella-delivered codon-optimized outer inflammatory protein DNA vaccine enhances protection in Helicobacter pylori infected mice. Vaccine 2012; 30: 5310-5315.
40. Chen J, Li N, She F. Helicobacter pylori outer inflammatory protein DNA vaccine-loaded bacterial ghost enhances immune protective efficacy in C57BL/6 mice. Vaccine 2014; 32: 6054- 6060.
41. Akhiani AA, Pappo J, Kabok Z, Schon K, Gao W, Franzen LE, Lycke N. Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells. J Immunol 2002; 169: 6977-6984.
42. Garhart CA, Nedrud JG, Heinzel FP, Sigmund NE, Czinn SJ. Vaccine-induced protection against Helicobacter pylori in mice lacking both antibodies and interleukin-4. Infect Immun 2003; 71: 3628-3633.
43. Sutton P. Helicobacter pylori vaccines and mechanisms of effective immunity: is mucus the key? Immunol Cell Biol 2001; 79: 67-73.
44. Ansorge S, Reinhold D, Lendeckel U. Propolis and some of its constituents down-regulate DNA synthesis and inflammatory cytokine production but induce TGF-β1 production of human immune cells. J Biosciences 2003; 58: 580-589.
45. Lee YJ, Kuo HC, Chu CY, Wang CJ, Lin WC, Tseng TH. Involvement of tumor suppressor protein p53 and p38 MAPK in caffeic acid phenethyl ester-induced apoptosis of C6 glioma cells. Biochem Pharmacol 2003; 66: 2281-2289.
46. Fischer G, Vidor T. Propolis as an immune system modulator substance. In: Oroli N, Bai I, editors. Scientific Evidence of the Use of Propolis in Ethnomedicine. Kerala, India: Transworld Research Network; 2008. pp. 133-147.
47. Sforcin JM. Propolis and the immune system: a review. J Ethnopharmacol 2007; 113: 1-14.